These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20436301)

  • 1. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.
    Zhao CY; Grinkevich VV; Nikulenkov F; Bao W; Selivanova G
    Cell Cycle; 2010 May; 9(9):1847-55. PubMed ID: 20436301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
    Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
    Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
    Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
    Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
    Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
    Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.
    Espinoza-Fonseca LM
    Theor Biol Med Model; 2005 Sep; 2():38. PubMed ID: 16174299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
    Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J
    Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving pharmacological rescue of p53 function: RITA targets mutant p53.
    Girardini JE; Del Sal G
    Cell Cycle; 2010 Jun; 9(11):2062. PubMed ID: 20559030
    [No Abstract]   [Full Text] [Related]  

  • 9. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
    Issaeva N; Bozko P; Enge M; Protopopova M; Verhoef LG; Masucci M; Pramanik A; Selivanova G
    Nat Med; 2004 Dec; 10(12):1321-8. PubMed ID: 15558054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis).
    Wang Z; Zhang X; Luo Y; Song Y; Xiang C; He Y; Wang K; Yu Y; Wang Z; Peng W; Ding Y; Liu S; Wu C
    Cell Death Dis; 2024 May; 15(5):375. PubMed ID: 38811536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
    Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
    Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.
    Kazemi A; Safa M; Shahbazi A
    Hematology; 2011 Jul; 16(4):225-31. PubMed ID: 21756539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
    Gottlieb A; Althoff K; Grunewald L; Thor T; Odersky A; Schulte M; Deubzer HE; Heukamp L; Eggert A; Schramm A; Schulte JH; Künkele A
    Oncotarget; 2017 Apr; 8(17):27882-27891. PubMed ID: 28427187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.
    Saha MN; Jiang H; Yang Y; Zhu X; Wang X; Schimmer AD; Qiu L; Chang H
    PLoS One; 2012; 7(1):e30215. PubMed ID: 22276160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
    Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
    Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system.
    Andreotti V; Ciribilli Y; Monti P; Bisio A; Lion M; Jordan J; Fronza G; Menichini P; Resnick MA; Inga A
    PLoS One; 2011; 6(6):e20643. PubMed ID: 21674059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chk2 mediates RITA-induced apoptosis.
    de Lange J; Verlaan-de Vries M; Teunisse AF; Jochemsen AG
    Cell Death Differ; 2012 Jun; 19(6):980-9. PubMed ID: 22158418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.
    Saha MN; Jiang H; Mukai A; Chang H
    Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.
    Di Cintio A; Di Gennaro E; Budillon A
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):1-13. PubMed ID: 19663772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.